BIOA Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of -890.97% compared to Bioage Labs's net margin of -6.61%. Bioage Labs's return on equity of -- beat Integra Lifesciences Holdings's return on equity of -1.88%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 47.78%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 31.1%. Given that Bioage Labs has higher upside potential than Integra Lifesciences Holdings, analysts believe Bioage Labs is more attractive than Integra Lifesciences Holdings.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Bioage Labs's net income of -$12.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Bioage Labs's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.58x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -890.97% compared to Bioage Labs's net margin of 26.7%. Bioage Labs's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 47.78%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $797.21 which suggests that it could grow by 35.5%. Given that Bioage Labs has higher upside potential than Regeneron Pharmaceuticals, analysts believe Bioage Labs is more attractive than Regeneron Pharmaceuticals.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.3% to investors and pays a quarterly dividend of $0.88 per share. Bioage Labs pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Bioage Labs's net income of -$12.9M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Bioage Labs's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 4.77x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Reshape Lifesciences has a net margin of -890.97% compared to Bioage Labs's net margin of -68.98%. Bioage Labs's return on equity of -- beat Reshape Lifesciences's return on equity of -172.58%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 47.78%. On the other hand Reshape Lifesciences has an analysts' consensus of -- which suggests that it could grow by 30362.15%. Given that Reshape Lifesciences has higher upside potential than Bioage Labs, analysts believe Reshape Lifesciences is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Reshape Lifesciences has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.008%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Reshape Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Reshape Lifesciences pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are larger than Reshape Lifesciences quarterly revenues of $1.1M. Bioage Labs's net income of -$12.9M is lower than Reshape Lifesciences's net income of $1.5M. Notably, Bioage Labs's price-to-earnings ratio is -- while Reshape Lifesciences's PE ratio is 0.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 0.01x for Reshape Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -890.97% compared to Bioage Labs's net margin of -30.29%. Bioage Labs's return on equity of -- beat Treace Medical Concepts's return on equity of -47.17%.

Bioage Labs has a consensus price target of $6.00, signalling upside risk potential of 47.78%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 65.45%. Given that Treace Medical Concepts has higher upside potential than Bioage Labs, analysts believe Treace Medical Concepts is more attractive than Bioage Labs.

Bioage Labs has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bioage Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioage Labs pays -- of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Bioage Labs quarterly revenues are $1.5M, which are smaller than Treace Medical Concepts quarterly revenues of $52.6M. Bioage Labs's net income of -$12.9M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, Bioage Labs's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioage Labs is -- versus 1.74x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.